Analyst consensus rating
Biofrontera Analyst Rating: Strong Buy
BFRI is rated Strong Buy by 2 analysts with a $6.00 target. As of 2026-08-21.
Direct answer
Biofrontera's consensus rating is Strong Buy.
2 analysts are included in the current consensus when a coverage count is available.
The same consensus reports an average price target of $6.00.
Forecast evidence checked August 21, 2026.
Get free Biofrontera email updates.
Bullstory sends one daily email when new analysis or important company news is available.
Verified data
- Current price
- $1.48
- Average price target
- $6.00
- High price target
- $9.00
- Low price target
- $3.00
- Low target gap
- +102.7%
- Target upside
- +305.4%
- High target gap
- +508.1%
- Target range width
- 405.4%
- Consensus rating
- Strong Buy
- Analysts
- 2
- Evidence date
- August 21, 2026
- Valid through
- August 28, 2026
Explore related company data
Read the frequently asked questions.
What is the analyst consensus rating for Biofrontera?
Biofrontera has a verified Strong Buy consensus. The same dataset has an average price target of $6.00.
How far are Biofrontera's low and high targets from the recorded price?
The low target implies +102.7%, while the high target implies +508.1%.
How many analysts are included in Biofrontera's consensus?
The verified consensus includes 2 analysts.
How is Biofrontera's target upside or downside calculated?
The average target of $6.00 is divided by the recorded price of $1.48, then one is subtracted to produce +305.4%. This does not guarantee a future return.
When was Biofrontera's analyst forecast verified?
The data was verified on 2026-08-21. The dataset is valid through 2026-08-28.